Updated:
Wieland Capital
Robert Wieland established Wieland Capital in 2004 following the sale of ESPE. The firm manages capital generated by that transaction for subsequent...
Wieland Capital
Robert Wieland established Wieland Capital in 2004 following the sale of ESPE. The firm manages capital generated by that transaction for subsequent generations of the Wieland family. It operates exclusively from Munich and invests its own balance sheet. The office targets established mid-sized companies in the DACH region through buyouts, management buy-ins and succession situations. It also participates in selected growth financings and venture capital rounds. Asset classes include private equity, venture capital, residential real estate in Berlin, Leipzig and Dresden, and forestry holdings. Portfolio companies include Peptido, REMEMBER, HKT-Kabeltechnik, Ceranovis, Lifespin, Schlafender Hase, Noscendo, PhagoMed, i3 Membrane, Plasmion, RoamsysNext, Inductio, Cycuria and Dawn-Bio. Co-investors have included High-Tech Gründerfonds, Earlybird Venture Capital, Vsquared Ventures and Revent. The firm maintains a European geographic focus. Team size remains undisclosed. Robert Wieland serves as founder and managing director. Franck Godet joined in 2007 and Melissa Simon joined in 2023. The office holds membership in the Bundesverband Beteiligungskapital. No additional offices or adjacent philanthropic vehicles appear in public records. Wieland Capital structures investments as direct equity positions alongside founders and management. It offers management buy-in capital and maintains no fixed fund life or external LP commitments. This permanent-capital model distinguishes its holding periods from typical private-equity fund cycles.
General information
Firm type
Single Family Office
Year founded
2004
Location
Region
Europe
Country
Germany
City
Munich
Corporate office
Schumannstraße 4, 81679 Munich, Germany
Principals
Robert Wieland
Founder and Managing Director
Franck Godet
Partner and Managing Director
Melissa Simon
Partner
Sector focus
Frequently asked questions
Who runs investment decisions at Wieland Capital?
Robert Wieland serves as founder and managing director. Franck Godet acts as partner and managing director. Melissa Simon joined as partner in 2023 with a focus on pharma, life sciences and health tech.
How does Wieland Capital source proprietary deal flow?
The firm targets succession situations and management buy-ins in the DACH region. It maintains direct relationships with founders and management teams of mid-sized companies.
Does Wieland Capital participate in fund commitments or only direct deals?
The office executes direct equity investments and co-investments. It does not disclose external fund commitments.
What investment stages does Wieland Capital typically target?
The firm pursues buyouts, growth equity and venture capital situations. Equity tickets per transaction typically range from €2 million to €7 million.
Where does the underlying wealth come from?
The capital originates from the 2004 sale of ESPE, a dental-materials business founded by Robert Wieland's grandfather.
Does Wieland Capital maintain philanthropic structures, and how are they separated?
No philanthropic vehicles are disclosed in public materials. All listed activities relate to the family's direct investment portfolio.
What is Wieland Capital's known posture on co-investments alongside external GPs?
The firm co-invests with partners including High-Tech Gründerfonds, Earlybird Venture Capital and Vsquared Ventures in healthcare and technology rounds.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: